61 completed, 5 terminated, 2 withdrawn, 1 unknown. 36 Phase 2, 15 Phase 4, 13 Phase 1, 12 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 32, Terminated 3, Withdrawn 1 |
| Phase 4 | 15 | Completed 14, Unknown 1 |
| Phase 1 | 13 | Completed 12, Terminated 1 |
| Phase 3 | 12 | Completed 10, Terminated 2 |
| Not applicable | 2 | Completed 2 |
Follow Daclizumab: new trials by email Literature Review of Daclizumab trials Research Report on Daclizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab Daclizumab - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Biogen | 41 | 2017-04-18 | 2019-09-27 |
| Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 BIIB019 (Daclizumab) - Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 3 | Terminated | Biogen | 1501 | 2013-02-15 | 2019-12-04 |
| An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis Midazolam, Caffeine, S-warfarin - Relapsing-Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 133 | 2011-11-01 | 2017-03-14 |
| Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis BIIB019 (Daclizumab), trivalent seasonal influenza vaccine - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Completed | Biogen | 410 | 2010-03-31 | 2018-11-09 |
| Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists Rabbit Antithymocyte globulin, Daclizumab - End Stage Renal Disease | Not applicable | Completed | Medical University of South Carolina | 200 | 2009-03-01 | 2016-04-26 |
| Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant Low Molecular Weight Sulfated Dextran, Heparin, Mycophenolate Mofetil - Diabetes Mellitus, Type I | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-07-01 | 2014-06-12 | |
| Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery PEP-3-KLH conjugate vaccine, daclizumab, temozolomide - Malignant Neoplasms of Brain | Phase 1 | Completed | John Sampson | 16 | 2007-03-01 | 2016-01-21 |
| Efficacy of Islet After Kidney Transplantation Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab - Type 1 Diabetes Mellitus | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2007-01-01 | 2017-10-20 |
| Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch Thymoglobulin, Daclizumab, Plasmapheresis - Kidney Failure, Chronic | Phase 3 | Completed | Johns Hopkins University | 56 | 2007-01-01 | 2018-01-18 |
| B-Lymphocyte Immunotherapy in Islet Transplantation Allogeneic Pancreatic Islet Cells, Antithymocyte globulin, Daclizumab - Type 1 Diabetes Mellitus | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 2 | 2006-11-01 | 2016-03-21 |
| Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin - Diabetes Mellitus, Type 1 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 14 | 2006-10-01 | 2016-03-16 |
| Combination Daclizumab/Denileukin Diftitox to Treat Uveitis Daclizumab - Non-infectious Intermediate and Posterior Uveitis | Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2006-05-11 | 2017-07-02 |
| Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration Intravenous Daclizumab, Intravenous Infliximab, Observation - Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 2 | Completed | National Eye Institute (NEI) | 13 | 2006-02-01 | 2016-11-29 |
| Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Alemtuzumab, Daclizumab, Thymoglobulin - Transplant; Failure, Kidney | Phase 4 | Completed | University of Miami | 200 | 2006-02-01 | 2023-09-28 |
| Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD daclizumab, infliximab - Graft vs Host Disease | Phase 4 | Completed | University of Iowa | 3 | 2006-01-01 | 2017-02-20 |
| Phase I/II Thymus Transplantation With Immunosuppression #950 Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw - DiGeorge Anomaly, Complete DiGeorge Anomaly | Phase 1 / Phase 2 | Completed | Sumitomo Pharma Switzerland GmbH | 14 | 2005-12-19 | 2022-03-25 |
| Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation tacrolimus, mycophenolate mofetil, daclizumab - Kidney Transplantation | Phase 3 | Completed | Astellas Pharma Inc | 198 | 2005-11-01 | 2015-06-26 |
| Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab - End-Stage Renal Disease, Living Donors | Phase 4 | Completed | University of Miami | 38 | 2005-11-01 | 2010-01-12 |
| CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation Campath, Daclizumab - Kidney Transplantation, Kidney Diseases | Phase 4 | Completed | EMagnusson | 123 | 2005-10-01 | 2021-09-29 |
| Multicenter Uveitis Steroid Treatment (MUST) Trial fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed - Uveitis | Phase 4 | Completed | JHSPH Center for Clinical Trials | 255 | 2005-09-01 | 2016-11-25 |
Showing 20 of 69. Sign in to see all of them.
Diabetes Mellitus, Type 1 (8) · Uveitis (7) · Multiple Sclerosis (6) · Kidney Failure, Chronic (5) · Multiple Sclerosis, Relapsing-Remitting (5) · Diabetes Mellitus, Insulin-Dependent, 10 (4) · Hypoglycemia (4) · Graft vs Host Disease (3) · Lymphoma (3) · Autoimmune Diseases (2) · Diabetes Mellitus (2) · Hodgkin Disease (2) · Kidney Diseases (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2)
National Institute of Allergy and Infectious Diseases (NIAID) (9) · National Eye Institute (NEI) (8) · Hoffmann-La Roche (5) · Biogen (4) · University of Miami (4) · Astellas Pharma Inc (2) · Facet Biotech (2) · Johns Hopkins University (2) · National Cancer Institute (NCI) (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Rockefeller University (2) · University Hospital, Lille (2) · AstraZeneca (1) · Baylor College of Medicine (1)
United States (55) · Canada (10) · Germany (7) · France (6) · United Kingdom (6) · Italy (5) · Poland (5) · Sweden (5) · Belgium (4) · Czechia (4) · Hungary (4) · Australia (3) · Spain (3) · India (2) · Israel (2)
James Krueger, MD, PHD (2) · Adam G McLean, FRCP, DPhil (1) · Ali Naji, MD, PhD (1) · Alireza Minagar, M.D. (1) · Anders Hartmann, MD (1) · Andrew Goodman, M.D. (1) · Andrew Posselt, MD, PhD (1) · Bernhard Hering, MD (1) · Bijoyesh Mookerjee, MD (1) · Christopher Bever, M.D (1) · Christopher E Simpkins, M.D. (1)
PMID 27411694, PMID 24477186, PMID 10221490, PMID 10798738, PMID 12438948, PMID 12761269, PMID 15049798, PMID 15257060, PMID 16123718, PMID 16382014, PMID 16687625, PMID 17005949, PMID 18035553, PMID 18094377, PMID 18339140, PMID 18424759, PMID 18557726, PMID 18787222, PMID 19066739, PMID 19364933, PMID 19664754, PMID 19808924, PMID 20067954, PMID 20163990, PMID 20236866, PMID 20847709, PMID 21538345, PMID 21652026, PMID 21836540, PMID 21840602, PMID 21861971, PMID 21981661, PMID 22027927, PMID 22247489, PMID 22383993, PMID 22409563, PMID 22694733, PMID 22694755, PMID 22996144, PMID 23009139, PMID 23042974, PMID 23163490, PMID 23438305, PMID 23607606, PMID 24513787, PMID 25115882, PMID 25393157, PMID 25557762, PMID 26501236, PMID 26798977
2004 (1), 2005 (1), 2009 (1), 2016 (1), K12HD043494 (1), P30CA006516 (1), P30CA016056 (1), R01AI047040 (1), R01AI054843 (1), R21CA132891 (1), U01DK061055 (1), U10EY014660 (1), UC4DK097835 (1)